Managing hypertension in patients with renal disease and diabetes.

References 1. Clark WF, Churchill DN, Forwell L, Macdonald G, Foster S. To pay or not to pay? A decision and cost–utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy. CMAJ 2000;162(2):195-8. 2. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62. 3. Sackett DL, Snow JC. The magnitude of compliance and noncompliance. In: Haynes RB, Taylor DW, Sackett DL, editors. Compliance in health care. Baltimore: Johns Hopkins University Press; 1979. p. 11-23. 4. Eraker SA, Kirscht JP, Becker MH. Understanding and improving patient compliance. Ann Intern Med 1984;100:258-68. 5. Gibaldi M. Failure to comply: a therapeutic dilemma and the bane of clinical trials. J Clin Pharmacol 1996;36:674-82. 6. McKenney JM, Munroe WP, Wright JT. Impact of an electronic medication compliance aid on long-term blood pressure control. J Clin Pharmacol 1992;32:277-83. 7. Brand FN, Smith RT, Brand PA. Effect of economic barriers to medical care on patients’ noncompliance. Public Health Rep 1977;92:72-8. 8. Leibowitz A, Manning WG, Newhouse JP. The demand for prescription drugs as a function of cost-sharing. Soc Sci Med 1985;21:1063-9. 9. O’Brien B. The effect of patient charges on the utilisation of prescription medicines. J Health Econ 1989;8:109-32. 10. Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ 1999; 160(1):41-6. 11. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD. Persistence with treatment for hypertension in actual practice. CMAJ 1999;160(1):31-7.